Stemline Therapeutics’ SL-401 Phase 2 BPDCN Trial Results To Be Delivered Via Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Tomorrow

On June 03, 2016 Stemline Therapeutics, Inc. (Nasdaq:STML) reported that its SL-401 Phase 2 clinical data in blastic plasmacytoid dendritic cell neoplasm (BPDCN) will be the subject of an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting being held in Chicago, IL (Press release, Stemline Therapeutics, JUN 3, 2016, View Source [SID:1234512974]). The presentation will take place tomorrow, Saturday, June 4th, at 5 PM CT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the ASCO (Free ASCO Whitepaper) presentation are as follows:


Title: Results from Phase 2 registration trial of SL-401 in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Lead-in completed, Expansion stage ongoing
Presenter: Naveen Pemmaraju, M.D., MD Anderson Cancer Center
Abstract No.: 7006
Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date/Time: Saturday, June 4, 2016; 5:00 – 5:12PM CT
Location: Arie Crown Theater

Ivan Bergstein, M.D., Stemline’s Chief Executive Officer, noted, "We are honored that our Phase 2 results have been selected for oral presentation at ASCO (Free ASCO Whitepaper). We believe this selection underscores the exciting clinical data we have witnessed with SL-401, and highlights the increased awareness of BPDCN, a devastating malignancy with high unmet medical need."

Dr. Bergstein concluded, "Our investigators plan to provide updated enrollment figures, response rates and duration, as well as preliminary progression-free and overall survival data from the trial. Needless to say, we continue to remain extremely excited about this program and its impressive progress. Over the remainder of the year, we look forward to providing further clinical and regulatory updates relating to SL-401 and across our entire clinical pipeline."